About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. Address: 500 Technology Square, Cambridge, MA, United States, 02139
Foghorn Therapeutics Inc News and around…
Latest news about Foghorn Therapeutics Inc (FHTX) common stock and company :
Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.
Viewing insider transactions for Foghorn Therapeutics Inc.'s ( NASDAQ:FHTX ) over the last year, we see that insiders...
In trading on Tuesday, shares of Foghorn Therapeutics Inc (FHTX) crossed above their 200 day moving average of $13.89, changing hands as high as $13.90 per share. Foghorn Therapeutics Inc shares are currently trading off about 2.8% on the day..
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Value ETF (IWN), we found that the implied analyst target price for the ETF based upon its underlying holdings is $188.56 per unit.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
On Tuesday morning, 69 companies achieved new lows for the year. Intriguing Points: Las Vegas Sands ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history, investment philosophy, and hedge fund performance, go directly to the 5 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean […]
A look at the shareholders of Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) can tell us which group is most powerful. Large...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, today announced the closing of a Series C financing round totaling $88.9 million. Joining founder and principal backer Flagship Pioneering is Stage 1 Ventures, Bluwave Capital, Alexandria Venture Investments, and others. With this financing, Invaio has raised more than $142 million since its founding in 2018.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Before 10 a.m. ET Thursday, 8 stocks made new 52-week lows. Areas of Interest: The largest company in terms ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, announced today an agreement with the world-renowned Fundecitrus, Fund for Citrus Protection, located in Araraquara, Brazil. The agreement focuses on the collaboration to evaluate the use of a novel natural peptide to control the devastating disease Citrus Greening (HLB) in Brazilian citrus trees.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Foghorn Therapeutics Inc (FHTX) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
